Cambium Bio Ltd
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more
Cambium Bio Ltd - Asset Resilience Ratio
Cambium Bio Ltd (CMB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how Cambium Bio Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Cambium Bio Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Cambium Bio Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Cambium Bio Ltd Industry Peers by Asset Resilience Ratio
Compare Cambium Bio Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Cambium Bio Ltd (2013–2023)
The table below shows the annual Asset Resilience Ratio data for Cambium Bio Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.00% | AU$0.00 | AU$2.48 Million | -- |
| 2022-06-30 | 2.71% | AU$69.27K | AU$2.55 Million | -3.99pp |
| 2021-06-30 | 6.70% | AU$570.23K | AU$8.51 Million | -5.21pp |
| 2020-06-30 | 11.91% | AU$570.23K | AU$4.79 Million | -11.55pp |
| 2019-06-30 | 23.45% | AU$596.16K | AU$2.54 Million | -- |
| 2017-06-30 | 0.00% | AU$0.00 | AU$9.16 Million | -- |
| 2016-06-30 | 0.00% | AU$0.00 | AU$5.93 Million | -- |
| 2014-06-30 | 1.25% | AU$127.75K | AU$10.26 Million | -1.81pp |
| 2013-06-30 | 3.06% | AU$122.93K | AU$4.02 Million | -- |